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Aging is the leading risk factor for cardiovascular disease,diabetes, dementias including Alzheimer’s disease, andcancer, together accounting for the majority of debilitat-
ing illnesses worldwide1. Uncovering common therapeutic targets
to prevent or treat these diseases simultaneously could convey
enormous benefits to quality of life. It is therefore essential to
model the cellular processes culminating in these diverse maladies
through an understanding of the molecular changes underlying
healthy and pathological aging2. Accordingly, a variety of mole-
cular studies have been conducted in humans, including whole
genome analysis of long-lived individuals3, transcriptomic ana-
lyses of tissues4, plasma proteomic profiling5, and the exploration
of epigenetic control of aging clocks6. Recent organism-wide
RNA-sequencing data of whole organs and single cells across the
mouse lifespan provide an important and complementary data-
base from which to build models of molecular cascades in
aging7,8.
Functional improvement of aged tissues has been achieved by
an expanding number of techniques, ranging from dietary
restriction9 to senescent cell elimination and partial cellular
reprogramming. This also includes heterochronic parabiosis, in
which an old mouse is exposed to a young circulatory system.
These experiments point to systemic factors in the blood of young
mice that modulate organ function in aged animals10,11. Indeed,
the list of individual plasma proteins with beneficial or detri-
mental effects on different tissues is growing. It is likely, however,
that each plasma protein interacts with complex intracellular
regulatory networks, and that alterations to such networks are a
key component of aging and rejuvenation.
Non-coding ribonucleic acids like microRNAs (miRNAs)
represent essential players governing these molecular cascades, and
they show a highly complex spectrum of biological actions12–14.
MicroRNAs are a family of short single stranded non-coding RNA
molecules that regulate post-transcriptional gene silencing through
base-pair binding on their target mRNAs13, thereby regulating
most if not all cellular and biological processes15. Yet, their
involvement in the aging process and rejuvenation of aged tissues
is often ignored by transcriptomic studies and is thus largely
uncharacterized. A single microRNA targets not only untranslated
regions (UTRs) of numerous genes, but it can also bind multiple
sites within a single UTR16. Similarly, a UTR of a specific gene can
contain target sites for dozens or even hundreds of miRNAs. Since
their discovery, miRNA changes have been reported for almost all
cancers and many non-cancer diseases like Alzheimer’s
disease17,18, multiple sclerosis19, or heart failure20. And although
relatively sparse, several studies have measured aging miRNA
expression in different human and primate tissues21. For example,
Somel and co-workers analyzed miRNA, mRNA, and protein
expression linked to development and aging in the prefrontal
cortex of humans and rhesus macaques over the lifespan22. Like-
wise, changes of miRNA levels in aging human skeletal muscle
have been characterized23, as have miRNA levels in body fluids
such as serum24,25. In whole blood, we previously reported a sig-
nificant number of age-related miRNAs26, and Huan and co-
workers measured a selection of miRNAs by RT-qPCR in whole
blood from over 5000 individuals from the Framingham Heart
Study27. While these initial studies are intriguing, they can be
limited by the use of discrete time points, incomplete lifespan
coverage, limited cohort sizes, and incomplete miRNA panels.
Here, we performed a comprehensive characterization of all
2549 annotated miRNAs (miRBase V21) in 4393 whole blood
samples from both sexes across the lifespan (30–90 years). To
understand the relationship between healthy aging and disease,
we included 1334 healthy controls (HC), 944 patients with
Parkinson’s disease (PD), 607 with heart diseases (HD), 586
with non-tumor lung diseases (NTLD), 517 with lung cancer
(LC), and 405 with other diseases (OD) (Fig. 1a, b; Supple-
mentary Data 1).
Results
miRNA profiles are stronger associated with the age as com-
pared to the sex. We first sought to model healthy aging as a
baseline for understanding disease. As males have shorter life-
spans than females, and each sex suffers a different array of age-
related diseases, we investigated the interplay between age and sex
on blood miRNA profiles. Confirming our previous observation
in a cohort of 109 individuals26, we found that age has a more
pronounced influence than sex. In fact, 1568 miRNAs sig-
nificantly correlated with age, but only 362 correlated with sex
according to Benjamini–Hochberg adjusted p-values of the Wil-
coxon Mann–Whitney test (Fig. 2a, b). While 231 miRNAs
overlapped between these groups, this number was not significant
(two-sided Fisher’s exact test p-value of 0.35; Pearson’s Chi-
squared Test of 0.36), suggesting that, in general, those miRNAs
changing with age are shared by both sexes, and those specific to
one sex do not change with age. In consequence, the Spearman
correlation coefficient (SC) of age-related changes between males
and females was high (SC of 0.884, p < 10−16, Fig. 2c).
We next sorted miRNAs by their correlation with age,
regardless of their significance, and assigned each to one of 5
groups: strongly decreasing with age (cluster 1: 174 miRNAs, SC
<−0.2), moderately decreasing (cluster 2: 382 miRNAs; −0.2 <
SC <−0.1), unaltered (cluster 3: 1451 miRNAs; −0.1 < SC < 0.1),
moderately increasing (cluster 4: 368 miRNAs; 0.1 < SC < 0.2),
and strongly increasing (cluster 5: 174 miRNAs, SC > 0.2)
(Supplementary Data 2). As miRNAs regulate a diverse array of
critical pathways28, we performed microRNA enrichment
analysis and annotation (miEAA) on this sorted list, thereby
calculating a running sum of miRNAs associated with each of
~14,000 biochemical categories and pathways. We revealed a
remarkable disequilibrium between the number of pathways
related to downregulated miRNAs (76 pathways) and upregulated
miRNAs (620 pathways; adjusted p-value < 0.05; Supplementary
Data 3). This is even more striking considering the number of
miRNAs increasing or decreasing did not differ significantly (556
with SC <−0.1; 542 with SC > 0.1), and suggests that miRNAs
increasing with age have a higher functional relevance. Reassur-
ingly, for miRNAs decreasing with age we found “Negative
Correlated with Age” (p= 4 × 10−10) among the most significant
categories (Fig. 2d). A large fraction of the top pathways
regardless of the miRNA direction were enriched for brain
function and neurodegeneration, including “Downregulated in
Alzheimer’s Disease” (p= 10−5), “regulation of synaptic trans-
mission” (p= 0.028), and “APP catabolic processes” (p= 0.032)
(Fig. 2e, Supplementary Fig. 1a–l).
Although such linear correlation analyses can reveal mean-
ingful biological features, the importance of nonlinear aging
changes, such as those found for plasma proteins5 and tissue gene
expression, is becoming increasingly evident. We therefore aimed
to use the high temporal resolution of the dataset to more
thoroughly understand whole blood miRNA dynamics across the
lifespan. We first plotted miRNA trajectories for each of the 5
clusters (Supplementary Fig. 2), confirming many miRNAs
exhibit non-linear patterns. By comparing linear and nonlinear
correlations for each, we uncovered nonlinear changes in 116 of
the 1098 miRNAs altered with age, of which 90 decreased and 26
increased (Fig. 2f, g, Supplementary Data 4). A miEAA analysis
highlighted a significant enrichment of miRNAs following
nonlinear trajectories with aging in basically all human tissues29
(Fig. 2h). This finding stands out considering the high degree of
tissue specificity of miRNAs. We thus speculate that diseases
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affecting these organs might be associated with changes in blood
miRNA profiles.
miRNA arm shifts are associated with aging. A shift in the
expression of the 3’ and 5’ mature arm of miRNAs is observed
between different tissues30 tissues but also in healthy and dis-
eased conditions such as cancer31. We speculated that likewise
aging may affect the arm distribution and searched for respective
arm shift events. Indeed, we observed a correlation of the arm
specific expression in 40 cases (Supplementary Data 5). For 27
miRNAs (67.5%) we observed increasing 5’ mature expression
and decreasing 3’ expression over age while in 13 cases 32.5% of
cases the 3’ form increased and the 5’ form decreased. These
results indicate a generally increasing 5’ mature miRNA
expression with aging. The largest absolute increase of 5’ mature
expression was identified for miR-6786. A miRSwitch analysis































































































































































































Fig. 1 Study characteristics. a Study set up and analysis workflow from high-throughput data to a specific aging network. The cohort consist of
4393 samples of which the age distribution is provided. For the 4393 samples genome wide miRNA screening using microarrays has been performed. The
first analysis describes 1568 miRNAs that are correlated to age in healthy individuals. In the second step we identified disease specific miRNA changes with
aging and finally define a set of 1242 miRNAs that are not affected by diseases. Finally, to model regulatory cascades in healthy aging we related the miRNA
data to plasma proteins and identified a core aging network. b The circular plot shows the genome wide nature of our miRNA approach, all miRNAs from
miRBase V21 were included in the experimental analysis. We measured 4393 samples for the abundance of these miRNAs, resulting in a 2549 times 4393
data table containing 11.2 million miRNA measurements that correspond to over 2 × 108 spots on the arrays.
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with 5’ dominance mostly in plasma samples. For the miRNA
with the most decreasing 5’ expression ratio (miR-4423) we
found dominating 3’ expression mostly in breast milk, the heart,
testis, stem cells and blood cells. Our results thus suggest an
altered ratio of the 3’ to 5’ mature expression ratio that might be
attributed to or effect different tissues.
The association between age and miRNA expression is partially
lost in diseases. Although the cellular and molecular degeneration
of aging often instigates age-related disease, there are nonetheless
elderly individuals who have lived entirely disease-free lives. We
therefore asked what differentiates such healthy aging from aging
resulting in disease. For each disease and healthy controls, we
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lung 1.3 x 10–10
myocardium 1.3 x 10–10
skin 1.3 x 10–10
testis 1.3 x 10–10
thyroid 5.9 x 10–10
artery 7.2 x 10–10
pancreas 7.8 x 10–10
pleura 7.8 x 10–10
vein 7.8 x 10–10
adipocyte 1.7 x 10–9
kidney 1.8 x 10–9
esophagus 5.1 x 10–9
gallbladder 5.1 x 10–9
muscle 5.1 x 10–9
smallintestine 5.4 x 10–9
stomach 6.4 x 10–9
nerve 1.3 x 10–8
bone 2.8 x 10–8
fascia 2.8 x 10–8
lymphnode 2.8 x 10–8
liver 1.5 x 10–7
bladder 1.5 x 10–7
epididymis 1.5 x 10–7
prostate 1.5 x 10–7
colon 2.2 x 10–7
brain 2.7 x 10–7
duramater 1.4 x 10–6
spleen 2.3 x 10–6
spinalcord 3 x 10–6
tunicaalbuginea 3 x 10–6
arachnoidmater 4.2 x 10–4
not sig.
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computed the Spearman correlation (SC) with age for all 2549
miRNAs (Fig. 3a, Supplementary Data 6). Overall, healthy controls
reached the largest absolute SC, greater than twice that of the pooled
disease cohort, and larger than any individual disease. Using an
Analysis of variance, we found highly significant differences (p <
2.2 × 10−16) and a non-parametric Wilcoxon Mann–Whitney test
confirmed the significant differences of absolute Spearman corre-
lation in healthy versus diseased samples (p < 2.2 × 10−16). In line
with these findings, samples from healthy individuals showed far
more miRNAs with significant age correlations (Fig. 3b), suggesting
that the presence of an age-related disease may disrupt healthy aging
miRNA profiles (Wilcoxon Mann–Whitney test p < 2.2 × 10−16).
For example, lung cancer patients were enriched for a positive
correlation with age, while miRNAs in patients with heart disease
were enriched for negative correlation with age. We then compared
the miRNA trajectories from the 5 clusters of healthy individuals to
the matched clusters in diseased patients (Supplementary Fig. 2),
and similarly, miRNAs from diseased individuals show far weaker
aging patterns. This held true both when each disease was analyzed
separately, or pooled.
To determine the extent to which diseases affect miRNA
abundance compared to healthy controls, we computed the number
of differentially expressed miRNAs between cases and controls
using a sliding window analysis. That is, we first compared diseased
individuals aged 30–39 years to healthy individuals aged 30–39
years, then increased the window in increments of one year (31–40
years, 32–41 years, etc.) to the final window of 70–79 years (Fig. 3c,
Supplementary Fig. 3a, b). As the age distribution varied between
these groups, we excluded any window in which there were fewer
than 20 disease cases and 20 healthy controls. Interestingly, for all
diseases the number of differentially expressed miRNAs was high in
young adults but decreased sharply into middle age, plateauing
around age 60 for lung cancer and 50 for non-tumor lung diseases.
Heart diseases largely plateaued by the early 50s. Parkinson’s disease
(PD), on the other hand, reached a minimum around age 47 before
sharply increasing. With the exception of PD, these data show that
aged healthy and diseased individuals are more similar than
younger healthy and diseased individuals, perhaps suggesting that
aged healthy individuals share some phenotypic characteristics of
heart and lung disease.
We next asked if these diseases shared any miRNA alterations,
and surprisingly we found that those miRNAs most commonly
dysregulated were also those with the largest effect size (Fig. 3d).
These pan-disease miRNAs included miR-191-5p (Fig. 3e), which
targets mRNAs involved in cellular senescence28. We also
observed disease-specific miRNAs like miR-16-5p, which targets
the PI3K-Akt signaling pathway and microRNAs involved in lung
cancer28. In summary, miRNA expression seems to be orche-
strated in healthy aging with a loss of regulation in disease. In
addition to disease-specific miRNAs, there appears to be a group
of pan-disease miRNAs that change in a distinct manner. We
thus asked on the specificity of biomarkers for diseases, especially
in an age dependent context.
Distinct miRNA biomarker sets exist in young and old
patients. The previous analyses of biomarkers in diseases were
largely quantitative, i.e., we computed the number of dysregulated
miRNAs in diseases for young and old patients. Here, we set to
evaluate changes in the miRNA sets for young and old patients in
the diseases. In this context we made use of the dimension
reduction and visualization capabilities of self-organizing maps
(SOMs). First, we considered the effect sizes of miRNAs for the
two most global comparisons, i.e., healthy controls versus diseases
and old (60–79 years) versus young (30–59 years) individuals.
The heat map representation for the healthy versus disease
comparison (Fig. 4a) and for young versus old individuals
(Fig. 4b) highlights distinct patterns for the two comparisons and
indicates that the aging miRNAs are different from the general
disease miRNAs. This analysis however calls for a disease specific
consideration. To this end we computed for each of the four
diseases biomarkers in old and young patients using again the
effect size as performance indicator and the self-organizing map
analysis followed by a hierarchical clustering (Fig. 4c). While the
cluster heat maps identify larger differences between the disease
biomarker sets as compared to young and old biomarkers, also
the sets within the diseases vary greatly (Fig. 4c). In line with the
previous analyses we observe larger effects for all diseases but PD
in young patients (middle row of Fig. 4c). In old patients, the
respective biomarkers are partially lost. Only in few cases new
biomarkers emerge in old patients that are not present in young
patients. As the full annotation of the SOM grid shows, each SOM
cell has an average of 8 cluster members with a standard deviation
of 3.5 miRNAs (Supplementary Data 7). The distribution largely
corresponds to a normal distribution, only four cells (24, 62, 81,
and 82 in Supplementary Data 7) contain more than 15 miRNAs
(mean+ two times the standard deviation).
The previous analyses suggest distinct biomarker sets for young
and old patients in the different diseases. As a consequence,
future biomarker test based on miRNAs may not only be
established for a disease but for a specific age range of patients
with that disease.
Given the results from this and the previous section we
computed for each miRNA in each disease and each age window
Fig. 2 miRNAs dependency on age and gender. a Smoothed scatter plot of the two-tailed age and gender association p-value for 2549 miRNAs. P-values
for the sex are computed using Wilcoxon Mann–Whitney test and for the Spearman Correlation via the asymptotic t approximation. The p-values are
Benjamini–Hochberg adjusted. b Boxplot of the age and gender p-value from a for 2549 miRNAs. The box spans the 25% and 75% quantile, the solid
horizontal line represents the median and the whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from
the box. c Correlation of miRNAs with age in males and females. Gray dots: not significant; orange and blue dots: miRNAs significantly correlated with age
only in males or females; green dots: miRNAs significantly correlated with age in males and females. d Results of the miRNA enrichment analysis. Colored
curves in the background represent random permutations of miRNAs. The cluster membership is projected next to the order of miRNAs. The category
“negative correlated with age” is highly significant and confirms our data in general. Also, the category “downregulated in AD” is enriched with miRNAs
decreasing over age. e Regulation of synaptic transmission is among the categories being enriched in miRNAs going up with age. Moreover, APP catabolic
processes is another category being enriched in miRNAs going up with age. f Linear Pearson correlation versus non-linear distance correlation for the
association of age to miRNAs. Orange dots have a high non-linear correlation that is not explained by linear correlation and are decreasing with age, green
dots have a high non-linear correlation that is not explained by linear correlation and are increasing with. The orange dotted line represents a smoothed
spline and the four numbers in gray circles represent the position of miRNAs where examples are provided in g. g Examples of correlation for miRNAs with
age. (1) gray: no correlation; (2) orange dominantly positive linear correlation; (3) blue dominantly negative linear correlation; (4) non-linear correlation.
Each solid line is a smoothing spline. h Tissue enrichment for the miRNAs that are correlated with age in a non-linear fashion. The human model has all
organs highlighted in gray that are significantly enriched. The table on the right lists the organs with corresponding p-values. P-values have been computed
using the hypergeometric distribution and were adjusted for multiple testing using the Benjamini–Hochberg approach.
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the effect size (Supplementary Data 8). The respective supple-
mentary data provides detailed insights in how specific certain
miRNAs are for specific diseases and age ranges and can support
ongoing biomarker studies significantly.
All results obtained so far argue for a strong immunological
component of the miRNAs, and as a consequence of miRNA
target networks. Since our experimental system profiles whole
blood miRNAs, we set out to determine the cellular origin by
computational deconvolution.
White blood cells are the major repository of miRNAs in whole
blood. Circulating immune cells have been implicated in aging
and a variety of age-related diseases, and one of the most
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common diagnostic tests for disease is blood cell profiling. Since
miRNAs are known to be enriched in different blood cell types32,
we performed computational deconvolution of the whole blood
miRNA profile, thereby grouping miRNAs by their predicted cell
type(s) of origin (Fig. 5a). A total of 196 miRNAs were attributed
to one specific cell type, including 127 miRNAs arising from
monocytes. Most others derive from three or more types. For
example, the largest group of 139 miRNAs stems from a com-
bination of white and red blood cells (WBCs, RBCs), exosomes,
and serum. And the third largest group of 119 is restricted to six
types of WBCs. We also observed 31 miRNAs specific for NK
cells, 19 specific for T-helper cells, 11 specific for B cells, and
8 specific for cytotoxic T cells. Overall, for those miRNAs for
which we could assign a prospective origin, we found WBCs as
the main contributor, even though they represent a substantially
smaller volume of whole blood relative to RBCs and serum
(Fig. 5b).
We then applied this analysis to those miRNAs changing with
age, and found that those increasing appear to largely originate
from B cells, monocytes, NK cells, cytotoxic T cells, and serum
(Fig. 5c). In contrast, miRNAs decreasing with age are those
enriched in neutrophils, T helper cells, and RBCs. These data
indicate shifts in aging miRNA trajectories of specific blood cell
types (Supplementary Fig. 4). Interestingly, for the above cell
types, known age-related abundance changes largely follow
opposite trends: lymphocytes generally decrease with age while
neutrophils increase with age33. This suggests that cell-intrinsic
gene expression changes age may significantly contribute to the
observed whole blood miRNA profiles.
miRNAs associated with healthy aging regulate the expression
of plasma proteins. An increasing body of evidence points to
functional roles of systemic plasma proteins in aging and disease5.
These proteins may represent downstream targets of blood-borne
miRNAs. We thus compared our data to a recent dataset of
plasma proteins associated with age in healthy individuals5.
Because miRNAs regulate genes/proteins in a complex network,
miRNAs increasing with age do not necessarily lead to down-
regulation of all target genes/proteins, and vice versa. Accord-
ingly, we observed only one tendency: miRNAs decreasing with
age (cluster 1 and 2) showed a slight enrichment for regulating
proteins increasing with age (Fig. 6a). Considering such com-
plexity, we employed a network-based analysis. Using all pair-
wise interactions of miRNAs with plasma proteins, we first
computed a regulatory network (Fig. 6b). From this, we extracted
a core network containing the top 5% downregulated miRNAs
and the top 5% upregulated proteins, which was then further
refined by including only experimentally validated miRNA/target
genes mined from the literature34, as well as miRNA/target pairs
with an absolute Spearman correlation of at least 0.6. This
stringent core network consists of 36 miRNAs targeting 26 genes
(proteins) and splits into two larger and six smaller connected
components (Fig. 6c). The densest part of the core network
contains the axon guidance related semaphorin 3E (SEMA3E)
and serine and arginine rich splicing factor 7 (SRSF7), which were
targeted by 8 miRNAs including miR-6812-3p (Fig. 6d, Supple-
mentary Fig. 5, Supplementary Fig. 6). Intriguingly, there exist no
studies of this miRNA, but it targets SEMA3E in an age depen-
dent manner with a Spearman correlation of −0.89.
Finally, we investigated the possible cell type of origin of these
core miRNAs with deconvolution, which showed enrichment for
neutrophils, monocytes, and B cells (Fig. 6e). We then used
single-cell PBMC transcriptomic data to determine if SEMA3A or
SRSF7 were expressed in these same cell types. While SEMA3E
was not detectable, we did observe SRSF7 expression widely
across cell types, including neutrophils, monocytes, and B cells
(Fig. 6f, g). SRSF7 plays a role in alternative RNA processing and
mRNA export, but has no known role in aging or neurodegen-
eration. Further research will be required to determine if miRNAs
like miR-6812-3p do indeed target SRSF7 in these specific cell
types, and to uncover if this process contributes to the global
decline of transcription observed with age.
Discussion
Our analysis of blood derived microRNAs provides insights into
changes in microRNA abundance dependent on age, sex, and
disease. While age clearly contributes to expression changes, sex
has a more modest effect. In fact, most miRNAs show a similar
behavior over the lifespan in males and females. This is generally
in-line with recent results in transcriptomic mouse tissue aging7,8.
Generally, our results compare well to other studies of miRNAs in
aging27, especially regarding miRNAs increasing with age, for
which we observe high concordance. There are, however, miR-
NAs decreasing with age reported in the previous study for which
we did not find evidence. The most extreme examples are miR-
30d-5p and miR-505-5p, both increasing with age in our study in
the healthy individuals. Nonetheless, given different cohorts with
different ethnicity, varying age range, and distinct profiling
technologies, we observed remarkable concordance between the
studies.
Here, we observed that diseases globally disturb the normal
aging progression of blood-borne miRNAs. While linear
Fig. 3 Diseases miRNAs are affected by age effects. a Boxplot of the Spearman correlation coefficient for each miRNA to all samples, healthy individuals,
and patients. Group sizes: nHC= 1334, nPD= 944, nHD= 607, nNTLD, nLC= 517, nOD= 405. The box spans the 25% and 75% quantile, the solid horizontal
line represents the median and the whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box.
b Boxplot of p-values for the Spearman correlation coefficient of each miRNA to all samples, healthy individuals, and patients from a. Group sizes: nHC=
1334, nPD= 944, nHD= 607, nNTLD, nLC= 517, nOD= 405. The box spans the 25% and 75% quantile, the solid horizontal line represents the median and
the whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box. The p-values have been
computed via the asymptotic t approximation. c Number of deregulated miRNAs in disease groups depending on different ages in a sliding window
analysis. Each solid line is a smoothing spline (green–heart diseases; red–non tumor lung diseases; gray–lung cancer; blue–Parkinson’s disease). The areas
represent the 95% confidence intervals. For all disease groups, the number of deregulated miRNAs decreases with age while it increases for Parkinson’s
Disease. d Smoothed scatterplot showing the average effect size per miRNA dependent on the number of diseases where the miRNA is associated with. In
the lower right corner (the y-axis value of 1) the specific miRNAs with high effect sizes can be found. In the upper right corner, miRNAs with high effect
sizes independent of the disease are located. The two numbers represent the location of the examples provided in e and f. e Example of a miRNA that is
downregulated in heart diseases of younger patients, upregulated in older Parkinson’s patients and not deregulated in lung diseases. Each solid line is a
smoothing spline (green–heart diseases; red–non tumor lung diseases; gray–lung cancer; blue–Parkinson’s disease). The areas represent the 95%
confidence intervals. f Example of a miRNA from the lower right part of Fig. 3d. The miRNA is significant upregulated in lung cancer independent of age but
basically not associated with other diseases. Color codes of panels c, e, and f are matched. Each solid line is a smoothing spline (green–heart diseases;
red–non tumor lung diseases; gray–lung cancer; blue–Parkinson’s disease). The areas represent the 95% confidence intervals.
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Fig. 4 Disease specificity of miRNA biomarkers. a Heat map representation of the SOM analysis as a 10 × 10 grid with 100 entries. Each cell contains at
least one miRNA and up to 20 miRNAs. The full annotation of miRNAs to cells are provided in Supplementary Data 7). The cells are colored by the effect
size of miRNAs for the comparison in old versus young. Red cells contain miRNAs with effect sizes >0.5 that are upregulated and in blue miRNAs that are
downregulated with effect sizes <−0.5. b Same heat map as in a but colored for the difference in young versus old. The scale for the effect size has been
kept the same as a. Thus fewer yellow/red, as well as blue spots indicate overall lower effect sizes. c Clustering of the SOM results in biomarkers for the
four diseases and in all biomarkers independently of age, biomarkers for young patients and biomarker for old patients. The dendrogram has been
computed from hierarchical clustering (complete linkage on the Euclidean distance). In all cases the biomarkers cluster by disease and not by age and the
old biomarker set is closest to the all biomarker set while the young biomarker set has larger distances. Overall, NTLD and LCa markers are closest to each
other, second closest are heart biomarkers and most different PD biomarkers. The SOM cells clearly highlight differences between biomarkers for diseases
in young and old patients.
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Fig. 5 Blood cell deconvolution. a The distribution of miRNAs in the different blood compounds. The rows are sorted by the blood compounds given on the
right (RBC: red blood cell; CF: cell free), the columns are sorted according to a decreasing number of miRNAs. b Relative abundance of all miRNAs in the
different blood compounds. c Distribution of miRNAs in cell types. The green distribution is the background and presents the relative composition of 1451
miRNAs in cluster 3. The blue distribution represents miRNAs increasing by age (cluster 4&5) and are enriched e.g., in B cells and serum. The red
distribution represents miRNAs decreasing by age (cluster 1&2) and are enriched e.g., in neutrophils and RBCs.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19665-1 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5958 | https://doi.org/10.1038/s41467-020-19665-1 | www.nature.com/naturecommunications 9
modeling insufficiently explained changes with aging, distance
correlation analysis identified 90 miRNAs that were decreasing
and 26 that were increasing with age in a non-linear manner.
These effects are, however, frequently not disease specific. If
disease specific effects occur, they appear to establish themselves
in given time windows throughout live. For example, lung and
heart diseases show the largest effect sizes in the 4th to 5th decade
of life, and Parkinson’s disease showed the largest effect size in the
6th to 7th decade. All known biological factors including age, sex,
and disease status together only explained part of the overall data
variance. Thus, unknown biological variables and technical fac-
tors also contribute to miRNA abundance.
Our results underline not only the importance of age as a con-
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incorporated into the definition of disease biomarkers. The age
dependency of miRNA biomarkers may be even more prominent
for acute diseases that are accompanied by drastic molecular chan-
ges. Furthermore, the influence of a disease on healthy aging miRNA
patterns suggests that it is conceivable to define “negative bio-
markers”, i.e., biomarkers that reflect the degree of disturbance of a
given time-dependent pattern typically found in healthy individuals.
miRNAs comprise complex gene regulatory networks, and it is
essential to identify the miRNA-targets that are regulated by a
given miRNA network. However, this is already a demanding task
for static networks, and it becomes even more challenging when
considering how entire networks change with age. We attempted
to overcome this complexity and identify a core miRNA network
by implementing several stringent criteria: (i) the inclusion of
miRNA-gene pairs only if experimental evidence exists, (ii) lim-
iting the analysis to the top 5% of miRNAs decreasing with age,
and (iii) the top 5% of proteins increasing with age and with
pairwise absolute correlation of at least 0.6. This stringent para-
meter set identified a core network of 36 miRNAs and 26 proteins
organized in two larger hubs with eight miRNAs targeting the
axon guidance related semaphorin 3E (SEMA3E) and serine and
arginine rich splicing factor 7 (SRSF7). Semaphorines play crucial
roles during the development of the nervous system, especially in
the hippocampal formation35. SEMA3E suppresses endothelial
cell proliferation and angiogenic capacity, and in complex with
PlexinD1 it inhibits recruitment of pericytes in endothelial cells36.
Since we did not detect SEMA3E mRNA expression in single
blood cell data we also explored other sources such as the
Genotype-Tissue Expression (GTEx) project37. But also in the
GTEx data no expression for the gene was reported in bulk
sequencing data. It thus remains unclear how or if these miRNAs
directly or indirectly impact SEMA3E protein levels in plasma. In
this context, low abundant fractions of the blood such as exo-
somes might play a role. However, SRSF7, which belongs to a
protein family linking alternative RNA processing to mRNA
export38, is expressed across a variety of circulating immune cells.
This is intriguing as no role in aging or neurodegeneration
is known.
Often, different technologies are available for high-throughput
studies. To characterize the complete miRNome, usually micro-
arrays or high-throughput sequencing are used. The choice of the
best technology depends both, on technical factors and on the
underlying biological question to be addressed. We decided to use
microarray technology mostly because of the high dynamic range
of blood miRNAs. In whole blood, the majority of reads
(90–95%) are matching to few (2–5) miRNAs39. While generally a
depletion is feasible40, it bears the risk to alter the profile of other
miRNAs especially since it has to be tailored for the respective
sequencing technology. To use microarrays has however also
disadvantages. MicroRNAs are often modified and build so-called
isomiRs and basically all human miRNAs express different iso-
forms41. Likewise, data from the Rigoutsos lab demonstrate the
importance and presence of isomiRs42. To address the age specific
expression of isomiRs, single nucleotide resolution is required.
Improved library preparation and sequencing methods together
with increasing read numbers per sample will likely allow for an
in-depth characterization of isomiRs in challenging specimens
such as whole blood.
Another aspect for respective studies is the underlying speci-
men type. A literature search reveals that for human miRNA
biomarker studies mostly plasma, serum, and blood cells (either
PBMCs or whole blood) are considered with a more recent trend
towards exosomes. Since we are interested in the connection of
miRNA expression and the immune system by analyzing multiple
diseases43 we measured blood cells. Different aspects can be used
to provide an even more comprehensive systemic picture of
miRNAs and aging. First, the cell free part of the blood is also
correlated to miRNA aging44,45. One important aspect are vesi-
cles. Cellular senescence for example contributes to age-
dependent changes in circulating extracellular vesicle cargo46.
Moreover, the differential loading of vesicles is correlated to
different human diseases47–49. Likewise, for the cellular part,
resolution can be increased. For example, the miRNomes could be
investigated per blood cell type50. One challenge is in that the
purification of the different cell types by different isolation
techniques potentially alters the miRNA content. Positive and
negative selection, as well as Fluorescence-activated cell sorting
(FACS) have a highly significant influence on the physiological
miRNA content32. Here, single cell miRNA profiling might help
to improve our understanding of age-related miRNA patterns in
the future. At best, single cell miRNA data and cell free miRNA
profiles are combined in the future using advancing sequencing
technologies. Finally, such data might further our understanding
of miRNAs in aging, diseases and their interplay with organ
patterns that are only partially understood29,51.
Over recent years, numerous studies have emerged highlighting
systemic molecular aging factors detected with different omics
technologies, including epigenetics, transcriptomics, and pro-
teomics. Our study specifically extends our knowledge of blood
and plasma-based miRNA patterns in aging. In our study we
observe non-linear miRNA aging patterns. Moreover, the high
degree of age-related biomarker patterns challenges the concept
of age independent miRNA biomarker profiles, calling for dif-
ferent statistical models in aged and younger individuals. The
changes with aging are not only attributed to one mature form,
we also provide detailed insights into changes of the usage of the
3’ and 5’ mature arms in aging.
Furthering our understanding of age-related miRNA changes
in healthy individuals and diseased patients will not only increase
our understanding of age-related blood-borne gene regulation,
but also improve miRNA-based biomarker development, and aid
the development of RNA-based therapies.
Methods
Cohort. In this study, we processed data from ntotal= 4433 whole blood samples.
We excluded 40 individuals (0.9%) because of insufficient data quality or missing
clinical or demographic information. The final cohort consists thus of 4393 sam-
ples. These include unaffected controls (nHC= 1,334), Parkinson’s Disease (nPD=
944), heart diseases (nHD= 607), non-tumor lung diseases (nNTLD= 586), lung
cancer (nLC= 517), and other diseases (nOD= 405). The diseases can be split
further in sub-classes. For lung cancer, we included non-small cell, as well as small
Fig. 6 Age related miRNAs are correlated to age related proteins. a Correlation of miRNAs to proteins. miRNAs and proteins are sorted by increasing
correlation with age. Thin lines are miRNA/gene interactions between top/bottom 10% of miRNAs and proteins. Numbers represent actual count of edges.
b, c Core network. Proteins (larger nodes) are targeted by miRNAs (smaller nodes). Edge width correspond to the correlation. Blue nodes represent
increase with age, red nodes decrease with age. The outer circles of the protein nodes indicate an expected an influence of the miRNAs leading to an
increase with age. Panel c represents a more stringent version of the network from panel b. d One representative example of an edge from the network in b,
c: SEMA3E and miR-6812-3p. Each dot represents all individuals in a time interval of 10 years, shifted between 30 and 70 years. SEMA3E is high expressed
in older individuals while miR-6812-3p is low expressed (dark red points in the upper right corner). In young individuals the pattern is opposite (tale points
in the lower right corner). e Blood cell compound distribution. miRNAs from the core network come from neutrophils, monocytes and B cells. f Violin plot of
expression of SRSF7 in human blood cells. g UMAP embedding of human blood cells colored by expression of SRSF7.
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cell lung cancer. For non-small cell lung cancer, we can further divide them in
adenocarcinoma and squamous cell carcinoma. These split in low grade and high-
grade tumors according to the TNM grading. The lung cancer cohort has been
previously described in more detail52. The heart diseases include coronary artery
disease, dilated cardiomyopathies and acute coronary syndrome. The non-tumor
lung diseases include mostly chronic obstructive pulmonary diseases, the other
diseases include sepsis, liver cirrhosis, breast cancer, endometriosis, and melanoma
patients. We aggregate the diseases to an organ level (heart, brain and lung). Only
for the lung we split the cohort in cancer and non-cancer samples. This aggregation
level has been selected in a manner to be able to distinguish between healthy and
diseased aging by having sufficient cohort sizes. Detailed diagnoses for each sample
are provided in Supplementary Data 1. All participants gave informed consent. The
local ethics committee of Saarland University approved the study. The study has
been conducted in compliance with all relevant ethical regulations regarding the
use of human study participants.
RNA extraction and measurement of miRNAs. RNA from 4433 whole blood
samples in PAXgeneTubes (BD Biosciences, Franklin Lakes, NJ, USA) was isolated
using the PAXgene Blood miRNA Kit (Qiagen, Hilden, Germany) using manu-
facturers recommendation. The extractions were done manually or semi-
automatically on the Qiacube robot. The RNA was quantified using Nanodrop
(Thermo Fisher Scientific, Waltham, MA, USA) and the RNA integrity was
checked using a bioanalyzer with the RNA Nano Kit (Agilent Technologies, Santa
Clara, CA, USA). The genome-wide expression profiles of human mature miRNAs
was determined with Human miRNA microarrays and the miRNA Complete
Labeling and Hyb Kit (Agilent Technologies). The labeled RNA was hybridized to
the arrays for 20 h at 55 °C with 20 rpm rotation. The microarrays were subse-
quently washed twice, dried and scanned with 3 µm resolution in double-path
mode (Agilent Technologies). The raw data were extracted using the manufacturers
Feature Extraction software (Agilent Technologies). Details on the RNA extraction
and microarray measurement procedure have been also previously described53,54.
In difference to our previous studies we tried to further minimize any variability. In
this study, we thus only included genome wide miRNA profiles that have been
measured using the Agilent miRBase V21 biochip.
Blood cell deconvolution. To analyze the miRNA blood cell composition, we
made use of our previous study that presented a high-resolution representation of
human miRNAs in different blood compounds50. From the data, we asked which
miRNAs are present in at least one sample of the respective blood compound and
generated an upset plot from the data. In some detail, we included serum,
microvesicles, red blood cells, CD15, CD19, CD8, CD56, CD4, and CD14 cells.
Correlation of age and sex to miRNAs. To find associations between the sex and
the miRNA expression we applied 2-tailed non-parametric Wilcoxon
Mann–Whitney tests. To compute linear correlation values between the age and
miRNA expression values we computed the Pearson Correlation Coefficient (PC)
and Spearman Correlation (SC). Further, to detect potentially non-linear relations
between single miRNAs and the age we also computed the Distance Correlation
(DI) between age and sex. To relate the DI and the SC, we computed a smoothed
spline with eight degrees of freedom and computed the minimal Euclidean distance
of each data point from the spline. Points with a distance of 0.02 (the threshold of
0.02 has been computed by a histogram-based approach) were highlighted and are
considered to follow a non-linear trend with aging. In the further analyses, we
applied only the rank-based Spearman Correlation (SC) instead of the Pearson
Correlation that assumes linear effects in data. Beyond linear and non-linear
correlations between single miRNAs and the age we also performed different
standard dimension reduction technologies, including principal component ana-
lysis, t-stochastic neighborhood embedding (t-SNE) and Uniform Manifold
Approximation and Projection (UMAP). To calculate the fraction of variance
attributed to the age and sex we applied principal variant component analysis
(PVCA), originally developed to discover batch effects in microarray experiments.
Analysis of arm shift events. Recently, we developed the miRSwitch database and
analysis tool to identify and characterize human arm shift and arm switch events30.
To detect associations between aging and differential arm usage we considered the
following criteria. First, the percentage of the 5’ mature arm given the total
expression of 3’ and 5’ arm must correlate with an absolute Spearman Correlation
Coefficient > 0.2. Second, the correlation must reach a p-value of at least 0.05. The
p-value is computed by the R cor.test function via the asymptotic t approximation.
Third, the difference between the minimal and maximal percentage of 5’ arm
expression for any samples must exceed 0.2 (20%). As fourth and last condition,
the 3’ and 5’ mature form must have a different sign, i.e., the 5’ has to increase with
age and the 3’ to decrease or vice versa. The miRNAs that were discovered by this
procedure where then checked by miRSwitch.
Cluster analysis and miRNA enrichment analysis. We split the miRNAs in 5
groups, strongly decreasing with age (SC <−0.2), decreasing with age (SC between
−0.2 and −0.1), not changing with age (SC between −0.1 and 0.1), miRNAs
increasing with age (SC > 0.1 and <0.2) and miRNAs increasing strongly with age
(SC > 0.2). For each cluster, we computed smoothed splines for each miRNA and
the cluster average allowing three degrees of freedom. Further, we computed for
disjoint age windows of five years whether miRNAs are significantly higher or
lower in cases versus controls at an alpha level of 0.05 and colored them, respec-
tively, in red and green. To find categories that are significantly enriched either for
miRNAs increasing or decreasing over age we performed a miRNA enrichment
analysis using the miEAA tool55, which has been recently updated56. Thereby, for
over 14,000 categories running sum statistics are computed. The sorted list of
miRNAs (increasing correlation with age) is processed from left to right. Whenever
a miRNA is located in a category the running sum is increased otherwise it is
decreased. The running sum is then plotted along with 100 random permutation
tests. Notably, the p-value is not computed from the permutations but exactly by
using dynamic programming. A category showing a perfect “V” like shape would
contain miRNAs that are increasing over age while a category following a pyramid
like shape contains miRNAs that are decreasing over age.
Sliding window analysis based on Cohen’s d. Since p-values rely on the effect
size and the cohort size different group sizes bias the results frequently. In our
sliding window analysis, we observed substantial differences, i.e., cases and controls
are not equally distributed across the age range. We thus performed all analyses
using Cohen’s d as effect size. All effects with an absolute value of above 0.5 were
considered relevant. Negative effect sizes thereby characterize downregulation and
positive effect sizes upregulation. We computed effect sizes for each disease in
windows of 10 years, shifted by one year, starting from 30 and ending at 70 years
(i.e., the last window is from 70 to 79 years). Only when at least 20 cases and
control measurements were available effect sizes were computed. The calculated
effect sizes were then summarized and a smoothed spline with eight degrees of
freedom were computed.
Self-organizing map (SOM) for finding disease patterns. One task in high
dimensional data analysis is to group features and to generate lower dimensional
representation of high dimensional data. Self-organizing maps (SOMs) are one type
of artificial neural networks (ANNs), relying on competitive learning. As described
by Kohonen already in 198257, in a network of adaptive elements “receiving signals
from a primary event space, the signal representations are automatically mapped
onto a set of output responses in such a way that the responses acquire the same
topological order as that of the primary events”. From input data, a typically two-
dimensional discretized representation of the input space is derived that can be
visualized by heat maps. To compute self-organizing maps for patients and con-
trols in an age dependent manner we computed the effect size for each disease
group over all patients, for young patient (30–60 years) and for old patients (60–80
years) separately. Only 801 highest expressed miRNAs were included in this
analysis. For the biomarker sets, a 10 × 10 hexagonal som grid was used to train a
network. The data set was presented 10,000 times to the network. The learning rate
was set to be between 0.05 and 0.01, meaning that the learning rate linearly
decreased from 0.05 to 0.01 over the 10,000 iterations. To cluster the SOM cells, we
performed hierarchical clustering. In more detail, we applied the R hclust function
to carry out agglomerative complete linkage clustering. As distance measure we
computed the Euclidean distance using the R dist function.
Plasma proteomics measurements. We used data from a recent study investi-
gating the effect of aging on the human plasma proteome. In this study, 2925
proteins were measured using the SomaScan assay in 4264 subjects from the
INTERVAL and LonGenity cohorts5. The SomaScan platform is based on modified
single-stranded DNA aptamers binding to specific protein targets. Assay details
were previously described. Relative Fluorescence Units (RFUs) were log10-
transformed and we used a 10 years sliding window to estimate proteins trajec-
tories throughout lifespan.
Target analysis and target network analysis. The main biological function of
miRNAs is to bind the 3’ UTR of genes and to degrade the target mRNAs. In
reality, miRNAs and genes thereby follow a n:m relation, i.e., one miRNA can
regulate many genes and one gene is regulated by many miRNAs. Further, there
exist different confidence levels to assume a pair-wise regulation of a miRNA to a
target gene. Most relations are only predicted by one or several computational
analyses. Another set is composed of miRNA gene pairs with weak evidence, e.g.,
from microarray experiments. The most reliable category consists of miRNA gene
pairs with strong evidence, e.g., validated by reporter assays. We only considered
this most reliable set of miRNA gene interactions and extracted the set from the
miRTarBase database34,58. Our analysis highlighted that around 20% of miRNAs
are increasing with age, 20% are decreasing and 60% are not age dependent. We
assumed the same distribution for human plasma proteins changing with age and
asked how many miRNAs going down with age regulate genes/proteins going up
and down with age, respectively. Similarly, we asked how many miRNAs going up
with age regulate genes/proteins going up and down with the age.
To construct a reliable core network, we combined five stringed filtering
approaches and only considered those connections between miRNAs and genes
that fulfill all filtering criteria. In the least stringent version the filters include (a) a
strong experimental evidence of a target interaction from the literature; (b) one of
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the most decreasing miRNAs (5%) regulates (c) one of the most upregulated
proteins (5%) over aging. To avoid a bias towards genes/proteins that are targeted
only by one or few miRNAs, potentially also fragmenting the network, we (d) only
considered proteins that are regulated by more than eight miRNAs. Next, we
analyzed the correlation between miRNAs and genes/proteins in the network over
40 discrete age ranges from 30 to 70 years. Each age range thereby spans 10 years.
For the 40 data points corresponding to 40 age windows we computed the
Spearman correlation between miRNA expression in this age window and protein
expression. As last criterion we added (e) only edges that have an absolute
Spearman correlation of at least 0.6. This network has been visualized with the
igraph library. Nodes were colored with respect to changes in age and edges
weights relative to the absolute Spearman correlation.
Single cell analysis. We used data that have been made available by 10× genomics
(https://support.10xgenomics.com/single-cell-gene-expression/datasets/3.0.0/
pbmc_10k_v3). The profiles were subsequently processed with scater59 and scran60
with default parameters, cell type annotations with singleR61.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw microarray measurements are freely available for any scientific purpose upon
request as Excel Table and Tab Delimited Text file (110 MB) to data@ccb.uni-saarland.
de. The use of the data for commercial purposes is prohibited.
Code availability
The data analysis has been performed using the R software for statistical computation (R
3.3.2 GUI 1.68 Mavericks build (7288)) using freely available packages. The following
packages were used: ROC, RColorBrewer, preprocessCore, tsne, effsize, UpSetR,
kohonen, fmsb, igraph. All packages are available from Bioconductor or CRAN.
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